Statistical analysis in neuroimaging (referred to as "neurostatistical imaging") is important in clinical neurology. Here, neurostatistical imaging and its superiority for diagnosing dementia are reviewed. In neurodegenerative dementia, the proportional distribution of brain perfusion, metabolism, or atrophy is important for understanding the symptoms and status of patients and for identifying regions of pathological damage. Although absolute quantitative changes are important in vascular disease, they are less important than relative values in neurodegenerative dementia. Even under resting conditions in healthy individuals, the distribution of brain perfusion and metabolism is asymmetrical and differs among areas. To detect small changes, statistical analysis such as the Z-score -the number of standard deviations by which a patient's voxel value differs from the normal mean value -comparing normal controls is useful and also facilitates clinical assessment. Our recent fi nding of a longitudinal one-year reduction of glucose metabolism around the olfactory tract in Alzheimer's disease using the recently-developed DARTEL normalization procedure is also presented. Furthermore, a newly-developed procedure to assess brain atrophy with CT-based voxel-based morphometry is illustrated. The promising possibilities of CT in neurostatistical imaging are also presented.
makes it difficult to assess the slight changes by visual inspection of the original tomographic images. Statistical analysis comparing normal controls makes the slight changes clear because the asymmetry and inhomogeneity in normal controls can be canceled out. In many cases of neurodegenerative disease, the changes are too obscure to detect without using neurostatistical imaging.
To diagnose the disease underlying dementia, the symptoms or status of patients are assessed, the region of pathological damage is predicted, and the dysfunction or volume loss of the lesion or remote areas is estimated.
Combining the original tomographic images, neurostatistical imaging, and clinical information, the pattern of damage distribution is judged based on whether or not they match the suspected disease. Recently, more accurate analysis has been achieved due to the development of computer technology.
Historical Background of Neurostatistical Imaging
In 1994, Minoshima et al. [3] showed that glucose metabolism decreases in the posterior cingulate in
Alzheimer's disease (AD) using Neurostat (Department of Radiology, University of Washington, Seattle, WA [3] , Ohnishi et al. [4] applied VBM to AD patients. Subsequently, in 2004, brain amyloid deposition was visualized using PET [5] , and in 2013, even brain tau protein was observed using a PET scanner [6] .
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Findings in the Alzheimer Brain
In neurostatistical imaging, usually images from all participants in the patient and normal control groups are anatomically standardized into the same space using templates, and voxel-based comparisons are performed to detect the specific lesions associated with the target disease. This is one of the objective methods available to avoid subjectivity and dependence on an a priori hypothesis, and to adopt the principle of data-driven analysis [7] .
For example, group comparison between AD patients and normal controls shows a significant decrease in glucose metabolism in the posterior cingulate and precuneus in AD [8] . Also, Kogre et al. reported reduced perfusion in the posterior cingulate and precuneus in very early stages of AD using 99m Tc-ethylcysteinate dimer SPECT [9] .
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Morphologically, because gray-matter thickness reflects the number of residual neurons, MRI has been used to derive anatomical and tissue volume information for the gray and white matter. The VBM technique maps gray-matter or white-matter loss on a voxel-by-voxel basis after anatomical standardization. In patients with AD, a significant reduction of gray-matter volume in the hippocampal formation and the entorhinal cortex has been described [4, 10] .
Estimation of Evidence for Diagnosis of AD Using
Z-score Analysis
As described in the former section, the Z-score is calculated as: (mean voxel value of normal controls − patient voxel value) / standard deviation of normal controls ( To estimate the diagnostic accuracy of a Z-score map, a volume of interest (VOI) is placed on the Z-score map where a significant reduction was determined by group comparison [11] . By averaging the Z-scores within the VOIs and using these values as thresholds, the receiver operating characteristic (ROC) curves discriminating patients from controls are drawn and then the accuracy is calculated. From the results, the areas that contribute most are chosen as diagnostic tools.
Evidence for the discrimination of AD from other forms of dementia has accumulated. By evaluating atrophy using three-dimensional (3D) T1 images with MRI, using the VBM method and VOIs in the hippocampus and parahippocampus, Hirata et al. [10] reported a discrimination accuracy of 87.8% between AD in the very early stage (amnestic type of mild cognitive impairment) and agematched healthy controls. By evaluating the distribution of the decrease in brain glucose metabolism, Kawachi et al.
reported an accuracy of 88.5% using VOIs in the bilateral posterior cingulate gyri and the right parietotemporal cortex [12] . Using SPECT, we reported an accuracy of 86.2%
using VOIs in the posterior cingulate and precuneus [11] .
Evidence-based Practice for Clinical Discrimination of AD from Other Forms of Dementia
For MRI, more than 2 000 institutes in Japan use VSRAD® (Eizai Co., Ltd.) for Z-score analysis of brain volumetry.
In this software, tissue segmentation is fi rst applied to the 3D-volume T1-weighted image, and gray-matter and white- matter images are obtained from each individual. Then, diffeomorphic anatomical registration using the exponential Lie algebra (DARTE) algorithm in SPM8 is used for spatial normalization. Both gray-and white-matter atrophy can be estimated using this software.
For nuclear medicine images, in Japan, two types of software for Z-score analysis of SPECT images are mainly used, eZIS [13] (easy Z-score imaging analysis; Fujifilm RI Pharma Co., Ltd, Tokyo, Japan) and iSSP (Nihon MediPhysics Co., Ltd, Tokyo, Japan) [14] .
eZIS includes spatial normalization parameters in SPM2. Normal databases are included in this software and inter-institutional differences can be corrected. That is, correction can be made for data obtained in the institute where the database was built, using previously-scanned phantom data. Otherwise, an original database can be built. 
Preparation of Normal Database
Neuroimaging is affected by many factors, such as (1) age, race, sex, and education, (2) institution, machine, and reconstruction method, and (3) head position and functional activity during the build-up time when the functional image is obtained.
Concerning age, race, sex, and education, selection of the normal database affects the results of analysis.
The more similar the conditions, the higher the sensitivity obtained. However, as the precision of subject selection increases, the size of the database decreases. As for age, if each group in the normal database consists of only a single decade, then the number is less than a database with two or three decades. In many cases, the size of the normal database is limited, and conditions are usually merged.
As for institution, machine, and reconstruction method, data acquisition should be performed in the 
Neurostatistical Imaging of Other Neurodegenerative Dementias
Dementia with Lewy Bodies versus AD
Reduced occipital metabolism and perfusion or loss of dopamine transporters is used to supplement the clinical diagnosis of dementia with Lewy bodies (DLB). Recently, it has been reported that glucose metabolism in the posterior cingulate cortex in DLB [15] appears to be relatively spared compared with that in AD. Lim et al. [15] found that reduced glucose metabolism in the medial occipital area and the cingulate island is a highly specific sign of DLB, with specifi cities of 97% and 100%, respectively, while the sensitivity of visual inspection ranged from 43% to 50% for the medial occipital and from 62% to 86% for the cingulate island.
Using VBM with VSRAD®, Nakatsuka et al. [16] examined its ability to discriminate between DLB and AD. Atrophy in the midbrain, pons, and cerebellum was observed as white matter atrophy in DLB compared with PET scans were performed at an interval of 12 months, and all images were spatially normalized using the DARTEL algorithm and analyzed with SPM8. The one-year reduction of glucose metabolism in AD patients was significantly greater in the area surrounding the orbital sulcus, including from the subgenual area to the anterior olfactory nucleus (AON) in addition to the posterior cingulate and medial temporal lesions, where decreases in glucose metabolism have been described (Fig. 3) . Fouquet et al. [18] reported that although the largest annual decrease in metabolism occurs in the posterior cingulate-precuneus area, patients who convert to AD have a significantly greater decrease than non-converters in two ventro-medial prefrontal areas, the subgenual (BA25) and anterior cingulate (BA24/32).
Moreover, Villain et al. [19] suggested that hippocampal atrophy in AD patients progressively leads to disruption of the cingulum bundle and uncinate fasciculus, which in turn leads to glucose hypometabolism in the cingulate and subgenual cortices. We speculate that the AON may be included in this subgenual area where decreased metabolism occurs [20] . Pathologically, amyloid deposition and neurofibrillary changes have been reported in the AON of AD patients. The AON has connections to the piriform cortex, anterior amygdala, periamygdaloid cortex, rostral entorhinal cortex, hypothalamus, and habenula.
Due to these pathways, the AON is rich in dendrites and astrocytes, resulting in abundant glucose consumption in this small region. We also speculate that reduction of glucose metabolism in the AON is responsible for the olfactory disturbances in AD patients.
Prospective Application of Neurostatistical Imaging
Brain CT has more homogeneity and less distortion than MRI, even when using different machines or scan protocols.
It is also relatively economical and widely available.
Moreover, nowadays, CT data are easily available from routine PET/CT studies. We compared the results from CT-VBM with those from MRI-based VBM (MR-VBM) in the same individuals [21] . All of the AD patients showed positive 11 C-PiB accumulation and none of the cognitively normal controls showed an accumulation. In CT-VBM, the AD group showed a significant decrease of gray matter volume in the bilateral entorhinal cortex, left hippocampus, left anterior cingulate gyrus, right temporopolar area, and right head of the caudate, compared to a cognitively normal group (Fig. 4) . In MR-VBM, the AD group showed a signifi cant decrease of gray matter volume in the bilateral hippocampus and left entorhinal cortex at BA28 compared to the cognitively normal group (Fig. 4) . The most signifi cant atrophy was observed in the left hippocampus.
The results of Z-score analysis comparing one 11 C-PiB positive AD patient with a normal database are shown in 
